Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome:A Case Series
Background: The development of complement inhibitors has greatly improved the outcome of patients with atypical hemolytic uremic syndrome (aHUS), making kidney transplantation a more feasible option. Although prophylactic eculizumab therapy may prevent recurrent disease after transplantation, its necessity for all transplant recipients is debated. Study Design: A case series. Setting & Participants: Patients with aHUS who underwent living donor kidney transplantation after 2011 at 2 university centers, prospectively followed up with a protocol of eculizumab therapy limited to only recipien... Mehr ...
Verfasser: |
Duineveld, Caroline
Verhave, Jacobien C
Berger, Stefan P
van de Kar, Nicole C A J
Wetzels, Jack F M |
Dokumenttyp: |
Artikel |
Erscheinungsdatum: |
2017 |
Reihe/Periodikum: |
Duineveld , C , Verhave , J C , Berger , S P , van de Kar , N C A J & Wetzels , J F M 2017 , ' Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome : A Case Series ' , American Journal of Kidney Diseases , vol. 70 , no. 6 , pp. 770-777 . https://doi.org/10.1053/j.ajkd.2017.06.024 |
Schlagwörter: |
Acute Kidney Injury
/ Adult
/ Aged
/ Antibodies
/ Monoclonal
/ Humanized
/ Atypical Hemolytic Uremic Syndrome
/ BK Virus
/ Complement C3
/ Complement Factor H
/ Complement Inactivating Agents
/ Female
/ Follow-Up Studies
/ Graft Rejection
/ Humans
/ Immunosuppressive Agents
/ Kidney Transplantation
/ Living Donors
/ Male
/ Membrane Cofactor Protein
/ Middle Aged
/ Mutation
/ Netherlands
/ Polyomavirus Infections
/ Postoperative Complications
/ Recurrence
/ Retrospective Studies
/ Tumor Virus Infections
/ Young Adult
/ Journal Article |
Sprache: |
Englisch |
Permalink: |
https://search.fid-benelux.de/Record/base-26826339 |
Datenquelle: |
BASE;
Originalkatalog |
Powered By: |
BASE |
Link(s) :
|
https://hdl.handle.net/11370/ba8f7904-c167-4327-8cab-6666ead19834 |